Ergomed Acquires MedSource, Expanding US Oncology and Rare Disease CRO Footprint
- Ergomed acquired Houston-based MedSource CRO for $16.2M upfront plus $1.8M in shares and up to $7.0M earnout, adding 110+ US employees and offices in Houston, Raleigh, and Boston.
- MedSource brings $41M order book, $19.3M service fee revenue (2019), and 20+ years' experience in oncology and rare disease trials, complementing Ergomed's specialist expertise.
- Combined business expands Ergomed's US presence and order book to $192M+, expected to drive new awards and increase pipeline visibility in North American CRO and pharmacovigilance markets.
Operational Impact
Ergomed's acquisition of MedSource adds $41M contracted revenue and oncology/rare-disease trial capacity across three new US regional hubs, strengthening its North American CRO footprint and order-book visibility for 2021 and beyond.
Source: PrimeVigilance
Ergomed's PrimeVigilance Launches Japan Operations with Dedicated Safety Database
- PrimeVigilance Japan KK opened in Tokyo on 26 April 2021, offering pharmacovigilance and medical information services with a dedicated Japanese safety database.
- Expansion extends Ergomed's geographic footprint to Asia, complementing existing European operations and recent North American acquisitions (Ashfield PV, MedSource).
- New facility enables PrimeVigilance to serve international clients entering Japan's fourth-largest pharmaceutical market and domestic Japanese companies.
Operational Impact
Ergomed's Japan subsidiary adds post-approval pharmacovigilance and medical information capacity in Asia, enabling CRO clients to extend product safety coverage into a major regulated market with local language expertise and infrastructure.
Source: PrimeVigilance
Ergomed Acquires Ashfield Pharmacovigilance for $10M to Expand US Market
- Ergomed's PrimeVigilance division acquired Ashfield Pharmacovigilance Inc. (Cary, NC) for $10 million, adding 40+ clients and $9.8 million in contracted future revenues.
- Combined business expands North American pharmacovigilance coverage and strengthens Ergomed's US CRO platform for cross-selling broader services globally.
- Ashfield PV generated $11.6 million revenue and $0.9 million adjusted EBITDA in FY2019; acquisition expected to be immediately accretive and leverage PrimeVigilance's technology infrastructure.
Operational Impact
Ergomed's acquisition of Ashfield PV establishes a material US pharmacovigilance footprint in the Research Triangle that enables PrimeVigilance to offer North American coverage to existing global clients while providing a platform for Ergomed's broader CRO service expansion in North America.
Source: PrimeVigilance
Altasciences Preclinical CRO Services Span Toxicology, PK/PD, and Integrated Clinical Programs
- Altasciences operates 585,000 sq ft of preclinical facilities across four North American sites, supporting rodent and non-rodent safety studies, carcinogenicity, and PK/PD work.
- Service portfolio includes IND-enabling toxicology, bioanalysis, anatomic/clinical pathology, SEND reporting, and integrated preclinical-to-clinical programs with unified project management.
Operational Impact
Altasciences' four-site North American preclinical footprint and integrated preclinical-to-clinical workflow reduce sponsor handoff friction for IND-enabling programs moving into Phase 1 trials.
Source: Altasciences
References
- PrimeVigilance — [Ergomed Acquires MedSource, Expanding US Oncology and Rare Disease CRO Footprint](https://primevigilance.com/2020/12/15/press-release-ergomed-plc-medsource-acquisition)
- PrimeVigilance — [Ergomed's PrimeVigilance Launches Japan Operations with Dedicated Safety Database](https://primevigilance.com/2021/04/26/press-release-primevigilance-expands-operations-in-japan)
- PrimeVigilance — [Ergomed Acquires Ashfield Pharmacovigilance for $10M to Expand US Market](https://primevigilance.com/2020/01/13/press-release-primevigilance-acquires-ashfield-pharmacovigilance-inc)
- Altasciences — [Altasciences Preclinical CRO Services Span Toxicology, PK/PD, and Integrated Clinical Programs](https://www.altasciences.com/preclinical-research-services)